Nalidixic acid: Difference between revisions

	WikiDoc Resources for Nalidixic acid
Articles
Most recent articles on Nalidixic acid Most cited articles on Nalidixic acid Review articles on Nalidixic acid Articles on Nalidixic acid in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Nalidixic acid Images of Nalidixic acid Photos of Nalidixic acid Podcasts & MP3s on Nalidixic acid Videos on Nalidixic acid
Evidence Based Medicine
Cochrane Collaboration on Nalidixic acid Bandolier on Nalidixic acid TRIP on Nalidixic acid
Clinical Trials
Ongoing Trials on Nalidixic acid at Clinical Trials.gov Trial results on Nalidixic acid Clinical Trials on Nalidixic acid at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Nalidixic acid NICE Guidance on Nalidixic acid NHS PRODIGY Guidance FDA on Nalidixic acid CDC on Nalidixic acid
Books
Books on Nalidixic acid
News
Nalidixic acid in the news Be alerted to news on Nalidixic acid News trends on Nalidixic acid
Commentary
Blogs on Nalidixic acid
Definitions
Definitions of Nalidixic acid
Patient Resources / Community
Patient resources on Nalidixic acid Discussion groups on Nalidixic acid Patient Handouts on Nalidixic acid Directions to Hospitals Treating Nalidixic acid Risk calculators and risk factors for Nalidixic acid
Healthcare Provider Resources
Symptoms of Nalidixic acid Causes & Risk Factors for Nalidixic acid Diagnostic studies for Nalidixic acid Treatment of Nalidixic acid
Continuing Medical Education (CME)
CME Programs on Nalidixic acid
International
Nalidixic acid en Espanol Nalidixic acid en Francais
Business
Nalidixic acid in the Marketplace Patents on Nalidixic acid
Experimental / Informatics
List of terms related to Nalidixic acid

Nalidixic acid
Clinical data
AHFS/Drugs.com	Consumer Drug Information
Pregnancy; category	B U.S.;
Routes of; administration	Oral
ATC code	J01MB02 (WHO) ;
Legal status
Legal status	Not FDA approved for clinical use in the United States;
Pharmacokinetic data
Protein binding	90%
Metabolism	Partially Hepatic
Elimination half-life	6-7 hours, significantly longer in renal impairment
Identifiers
	IUPAC name 1-Ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid;
CAS Number	389-08-2 ;
PubChem CID	4421;
DrugBank	DB00779 ;
ChemSpider	4268 ;
UNII	3B91HWA56M;
KEGG	D00183 ;
ChEBI	CHEBI:100147 ;
ChEMBL	ChEMBL5 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C12H12N2O3
Molar mass	232.235 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C\2c1c(nc(cc1)C)N(/C=C/2C(=O)O)CC;
	InChI InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17) ; Key:MHWLWQUZZRMNGJ-UHFFFAOYSA-N ;
(verify)

VisualWikitext

Latest revision as of 19:47, 7 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Nalidixic acid (tradenames Nevigramon, Neggram, Wintomylon and WIN 18,320) is the first of the synthetic quinolone antibiotics.

In the technical sense, it is a naphthyridone, not a quinolone: its ring structure is a 1,8-naphthyridine nucleus that contains two nitrogen atoms, unlike quinoline, which has a single nitrogen atom.^[1]

Synthetic quinolone antibiotics were discovered by George Lesher and coworkers as a byproduct of chloroquine manufacture in the 1960s.^[1] Used clinically from 1967.^[1]

Nalidixic acid is effective primarily against gram-negative bacteria, with minor anti-gram-positive activity. In lower concentrations, it acts in a bacteriostatic manner; that is, it inhibits growth and reproduction. In higher concentrations, it is bactericidal, meaning that it kills bacteria instead of merely inhibiting their growth.

It has historically been used for treating urinary tract infections, caused, for example, by Escherichia coli, Proteus, Shigella, Enterobacter, and Klebsiella. It is no longer clinically used for this indication in the USA as less toxic and more effective agents are available.

It is also a tool in studies as a regulation of bacterial division. It selectively and reversibly blocks DNA replication in susceptible bacteria. Nalidixic acid and related antibiotics inhibit a subunit of DNA gyrase and topoisomerase IV and induce formation of cleavage complexes.^[2] It also inhibits the nicking-closing activity on the subunit of DNA gyrase that releases the positive binding stress on the supercoiled DNA.

Adverse effects

Hives, rash, intense itching, or fainting soon after a dose may be a sign of anaphylaxis. Common adverse effects include rash, itchy skin, blurred or double vision, halos around lights, changes in color vision, nausea, vomiting, and diarrhea. Nalidixic acid may also cause convulsions and hyperglycaemia,^[3] photosensitivity reactions,^[4] and sometimes haemolytic anaemia,^[5]^[6] thrombocytopenia^[7] or leukopenia. Particularly in infants and young children, has been reported occasionally increased intracranial pressure.^[8]^[9]^[10]

Overdose

In case of overdose the patient experiences headache, visual disturbances, balance disorders, mental confusion, metabolic acidosis and seizures.^[11]

Spectrum of bacterial susceptibility and resistance

Aeromonas hydrophila, Clostridium and Haemophilus are generally susceptible to nalidixic acid, while other bacteria such as Bifidobacteria, Lactobacillus, Pseudomonas and Staphylococcus are resistant.^[12]

Synthesis

EMME (Ethoxy Methylene Malonic Diethyl Ester)

References

↑ ^1.0 ^1.1 ^1.2 Emmerson AM, Jones AM (May 2003). "The quinolones: decades of development and use" (pdf). The Journal of Antimicrobial Chemotherapy. 51 Suppl 1 (Suppl 1): 13–20. doi:10.1093/jac/dkg208. PMID 12702699.
↑ Pommier, Y.; Leo, E.; Zhang, H.; Marchand, C. (2010). "DNA topoisomerases and their poisoning by anticancer and antibacterial drugs". Chem. Biol. 17: 421–433. doi:10.1016/j.chembiol.2010.04.012. PMID 20534341.
↑ Fraser AG, Harrower AD (Dec 1977). "Convulsions and hyperglycaemia associated with nalidixic acid". British Medical Journal. 2 (6101): 1518. doi:10.1136/bmj.2.6101.1518. PMC 1632822. PMID 589309.
↑ Ramsay CA (Aug 1973). "Photosensitivity from nalidixic acid". Proceedings of the Royal Society of Medicine. 66 (8): 747. PMC 1645105. PMID 4733958.
↑ Gilbertson C, Jones DR (Nov 1972). "Haemolytic anaemia with nalidixic acid". British Medical Journal. 4 (5838): 493. doi:10.1136/bmj.4.5838.493-a. PMC 1786728. PMID 4653901.
↑ Tafani O, Mazzoli M, Landini G, Alterini B (Oct 1982). "Fatal acute immune haemolytic anaemia caused by nalidixic acid". British Medical Journal. 285 (6346): 936–7. doi:10.1136/bmj.285.6346.936-a. PMC 1499997. PMID 6811074.
↑ Meyboom RH (Oct 1984). "Thrombocytopenia induced by nalidixic acid". British Medical Journal. 289 (6450): 962. doi:10.1136/bmj.289.6450.962. PMC 1443179. PMID 6435742.
↑ Boréus LO, Sundström B (Jun 1967). "Intracranial hypertension in a child during treatment with nalidixic acid". British Medical Journal. 2 (5554): 744–5. doi:10.1136/bmj.2.5554.744. PMC 1841777. PMID 6025983.
↑ Kremer L, Walton M, Wardle EN (Nov 1967). "Nalidixic acid and intracranial hypertension". British Medical Journal. 4 (5577): 488. doi:10.1136/bmj.4.5577.488-a. PMC 1748506. PMID 6055749.
↑ Deonna T, Guignard JP (Sep 1974). "Acute intracranial hypertension after nalidixic acid administration". Archives of Disease in Childhood. 49 (9): 743. doi:10.1136/adc.49.9.743. PMC 1649016. PMID 4419059.
↑ Eizadi-Mood N (Mar 2006). "Nalidixic acid overdose and metabolic acidosis". Cjem. 8 (2): 78. PMID 17175866.
↑ "Nalidixic acid spectrum of bacterial susceptibility and Resistance" (pdf). Toku-E. 2011-09-14. Retrieved 2012-05-14.
↑ Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP (Sep 1962). "1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents". Journal of Medicinal and Pharmaceutical Chemistry. 91. doi:10.1021/jm01240a021. PMID 14056431.
↑ Logemann W, Almirante L, Caprio L (Mar 1954). "Studien in der heterocyclischen Reihe. I. Mitteil.: Eine neue Synthese der 2.4-Diamino-6-alkyl-5-aryl-pyrimidine ("Daraprim")". Chemische Berichte. 87 (3): 435–439. doi:10.1002/cber.19540870324. DE 1933463 GB 1338023 BE 612258

External links

Template:MedlinePlusDrugInfo^{[dead link]}
"Nalidixic acid". HealthDigest.org.

Template:QuinoloneAntiBiotics

[jac2003-1] 1.0 ^1.1 ^1.2 Emmerson AM, Jones AM (May 2003). "The quinolones: decades of development and use" (pdf). The Journal of Antimicrobial Chemotherapy. 51 Suppl 1 (Suppl 1): 13–20. doi:10.1093/jac/dkg208. PMID 12702699.

[2] Pommier, Y.; Leo, E.; Zhang, H.; Marchand, C. (2010). "DNA topoisomerases and their poisoning by anticancer and antibacterial drugs". Chem. Biol. 17: 421–433. doi:10.1016/j.chembiol.2010.04.012. PMID 20534341.

[3] Fraser AG, Harrower AD (Dec 1977). "Convulsions and hyperglycaemia associated with nalidixic acid". British Medical Journal. 2 (6101): 1518. doi:10.1136/bmj.2.6101.1518. PMC 1632822. PMID 589309.

[pmid4733958-4] Ramsay CA (Aug 1973). "Photosensitivity from nalidixic acid". Proceedings of the Royal Society of Medicine. 66 (8): 747. PMC 1645105. PMID 4733958.

[pmid4653901-5] Gilbertson C, Jones DR (Nov 1972). "Haemolytic anaemia with nalidixic acid". British Medical Journal. 4 (5838): 493. doi:10.1136/bmj.4.5838.493-a. PMC 1786728. PMID 4653901.

[pmid6811074-6] Tafani O, Mazzoli M, Landini G, Alterini B (Oct 1982). "Fatal acute immune haemolytic anaemia caused by nalidixic acid". British Medical Journal. 285 (6346): 936–7. doi:10.1136/bmj.285.6346.936-a. PMC 1499997. PMID 6811074.

[pmid6435742-7] Meyboom RH (Oct 1984). "Thrombocytopenia induced by nalidixic acid". British Medical Journal. 289 (6450): 962. doi:10.1136/bmj.289.6450.962. PMC 1443179. PMID 6435742.

[pmid6025983-8] Boréus LO, Sundström B (Jun 1967). "Intracranial hypertension in a child during treatment with nalidixic acid". British Medical Journal. 2 (5554): 744–5. doi:10.1136/bmj.2.5554.744. PMC 1841777. PMID 6025983.

[pmid6055749-9] Kremer L, Walton M, Wardle EN (Nov 1967). "Nalidixic acid and intracranial hypertension". British Medical Journal. 4 (5577): 488. doi:10.1136/bmj.4.5577.488-a. PMC 1748506. PMID 6055749.

[pmid4419059-10] Deonna T, Guignard JP (Sep 1974). "Acute intracranial hypertension after nalidixic acid administration". Archives of Disease in Childhood. 49 (9): 743. doi:10.1136/adc.49.9.743. PMC 1649016. PMID 4419059.

[pmid17175866-11] Eizadi-Mood N (Mar 2006). "Nalidixic acid overdose and metabolic acidosis". Cjem. 8 (2): 78. PMID 17175866.

[12] "Nalidixic acid spectrum of bacterial susceptibility and Resistance" (pdf). Toku-E. 2011-09-14. Retrieved 2012-05-14.

[13] Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP (Sep 1962). "1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents". Journal of Medicinal and Pharmaceutical Chemistry. 91. doi:10.1021/jm01240a021. PMID 14056431.

[14] Logemann W, Almirante L, Caprio L (Mar 1954). "Studien in der heterocyclischen Reihe. I. Mitteil.: Eine neue Synthese der 2.4-Diamino-6-alkyl-5-aryl-pyrimidine ("Daraprim")". Chemische Berichte. 87 (3): 435–439. doi:10.1002/cber.19540870324. DE 1933463 GB 1338023 BE 612258

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

@@ Line 48: / Line 48: @@
 | StdInChIKey = MHWLWQUZZRMNGJ-UHFFFAOYSA-N
 }}
+__NOTOC__
+{{SI}}
+{{CMG}}
+==Overview==
 '''Nalidixic acid''' (tradenames '''Nevigramon''', '''Neggram''', '''Wintomylon''' and '''WIN 18,320''') is the first of the synthetic [[quinolone]] [[antibiotic]]s.
@@ Line 76: / Line 79: @@
 EMME ([[Ethoxy Methylene Malonic Diethyl Ester]])
-[[File:Nald Tab.png|none|center|700px|Naldixic acid synthesis:<ref>{{vcite2 journal | vauthors = Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP | title = 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents | journal = Journal of Medicinal and Pharmaceutical Chemistry | volume = 91 | date = Sep 1962 | pmid = 14056431 | doi = 10.1021/jm01240a021 }}</ref><ref>{{vcite2 journal | vauthors =Logemann W, Almirante L, Caprio L|title=Studien in der heterocyclischen Reihe. I. Mitteil.: Eine neue Synthese der 2.4-Diamino-6-alkyl-5-aryl-pyrimidine ("Daraprim") | journal = Chemische Berichte | date = Mar 1954 | volume = 87 | issue = 3 | pages = 435–439 | doi=10.1002/cber.19540870324}} {{Cite patent|DE|1933463}} {{Cite patent|GB|1338023}} {{Cite patent|BE|612258}}</ref> ]]
+[[File:Nald Tab.png|none|center|700px<ref>{{vcite2 journal | vauthors = Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP | title = 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents | journal = Journal of Medicinal and Pharmaceutical Chemistry | volume = 91 | date = Sep 1962 | pmid = 14056431 | doi = 10.1021/jm01240a021 }}</ref><ref>{{vcite2 journal | vauthors =Logemann W, Almirante L, Caprio L|title=Studien in der heterocyclischen Reihe. I. Mitteil.: Eine neue Synthese der 2.4-Diamino-6-alkyl-5-aryl-pyrimidine ("Daraprim") | journal = Chemische Berichte | date = Mar 1954 | volume = 87 | issue = 3 | pages = 435–439 | doi=10.1002/cber.19540870324}} {{Cite patent|DE|1933463}} {{Cite patent|GB|1338023}} {{Cite patent|BE|612258}}</ref> ]]
 == See also ==
@@ Line 83: / Line 86: @@
 == References ==
-{{reflist|33em}}
+{{reflist|2}}
 == External links ==

Clinical data

AHFS/Drugs.com	Consumer Drug Information
Pregnancy category	B U.S.
Routes of administration	Oral
ATC code	J01MB02 (WHO)
Legal status
Legal status	Not FDA approved for clinical use in the United States
Pharmacokinetic data
Protein binding	90%
Metabolism	Partially Hepatic
Elimination half-life	6-7 hours, significantly longer in renal impairment
Identifiers
IUPAC name 1-Ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid
CAS Number	389-08-2^Y
PubChem CID	4421
DrugBank	DB00779^Y
ChemSpider	4268^Y
UNII	3B91HWA56M
KEGG	D00183^Y
ChEBI	CHEBI:100147^Y
ChEMBL	ChEMBL5^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₂H₁₂N₂O₃
Molar mass	232.235 g/mol
3D model (JSmol)	Interactive image
SMILES O=C\2c1c(nc(cc1)C)N(/C=C/2C(=O)O)CC
InChI InChI=1S/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)^Y Key:MHWLWQUZZRMNGJ-UHFFFAOYSA-N^Y
(verify)